A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study

Journal of the American College of Cardiology

Volumn 58, Issue 4, 2011, Pages 395-401

  Fang, Margaret C ^a   Go, Alan S ^a,b   Chang, Yuchiao ^c   Borowsky, Leila H ^c   Pomernacki, Niela K ^b   Udaltsova, Natalia ^b   Singer, Daniel E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anticoagulants; atrial fibrillation; hemorrhage; risk prediction; warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 80052094564     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.03.031     Document Type: Article

References (18)

1. Hart, R., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
2. Bungard, T.J., Ghali, W.A., McAlister, F.A., et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol 19 (2003), 280–284.
3. Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V., Singer, D.E., Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 131 (1999), 927–934.
4. Go, A.S., Hylek, E.M., Chang, Y., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 290 (2003), 2685–2692.
5. Beyth, R., Quinn, L., Landefeld, C., Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105 (1998), 91–99.
6. Kuijer, P., Hutten, B., Prins, M., Buller, H., Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159 (1999), 457–460.
7. Kearon, C., Ginsberg, J.S., Kovacs, M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 (2003), 631–639.
8. Gage, B.F., Yan, Y., Milligan, P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006), 713–719.
9. Shireman, T.I., Mahnken, J.D., Howard, P.A., Kresowik, T.F., Hou, Q., Ellerbeck, E.F., Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130 (2006), 1390–1396.
10. Ruíz-Giménez, N., Suárez, C., González, R., et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism: Findings from the RIETE Registry. Thrombos Haemostas 100 (2008), 26–31.
11. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
12. Austin, P.C., Tu, J.V., Bootstrap methods for developing predictive models. Am Statistician 58 (2004), 131–137.
13. Kremers, W.K., Concordance for Survival Time Data: Fixed and Time-Dependent Covariates and Possible Ties in Predictor and Time: Technical Report Series #80. 2007, Mayo Clinic, Rochester, MN.
14. Pencina, M.J., D'Agostino, R.B., Steyerberg, E.W., Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30 (2011), 11–21.
15. Fang, M.C., Go, A.S., Chang, Y., Borowsky, L., Pomernacki, N., Singer, D.E., Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51 (2008), 810–815.
16. Fang, M.C., Go, A.S., Chang, Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120 (2007), 700–705.
17. Mant, J., Hobbs, R., Fletcher, K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007), 493–503.
18. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.